Treatment of Parkinsonism with Pagitane Hydrochloride

Abstract

Pagitane hydrochloride (1-phenyl-1-cyclopentyl-3-piperidino-l-propanol hydrochloride), a new synthetic for the treatment of Parkinson''s disease, was tested for its effects and side reactions in 142 patients that had done poorly on other available remedies. The study was continued for 15 months. It was found that Pagitane is a valuable addition to the armamentarium against parkinsonism. Ninety-four patients, or 66% of the group, were benefited to various degrees by the new compound. Side reactions of dryness of the mouth and blurring of vision were such as are commonly found with belladonna products and their congeners, but no toxic or disturbing reactions were noted among any of the patients. Pagitane exerts an effect against tremor, rigidity, and oculogyria. It controls sialorrhea and is a powerful cerebral stimulant. It may be combined with other drugs for the control of severe grades of rigidity and tremor.